Canaccord Genuity Upgrades Cardiome Pharma (CRME) to Hold
Get Alerts CRME Hot Sheet
Price: $2.33 --0%
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity upgraded shares of Cardiome Pharma (NASDAQ: CRME) from Sell to Hold in a mid-day research note Wednesday. The firm's price target was lowered from $1.50 to $0.85.
The downgrade follows Q4 results from Cardiome late Tuesday.
For an analyst ratings summary and ratings history on Cardiome Pharma click here. For more ratings news on Cardiome Pharma click here.
The downgrade follows Q4 results from Cardiome late Tuesday.
For an analyst ratings summary and ratings history on Cardiome Pharma click here. For more ratings news on Cardiome Pharma click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Reading (RDI) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
UpgradesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share